New trial testing novel combination immunotherapies in pancreatic cancer opens at Columbia University Medical Center/New York Presbyterian Hospital

 Gulam A. Manji, MD, PhD

Last month, Columbia University Medical Center/New York Presbyterian Hospital (CUMC/NYP) were proud to become the first site internationally to open and enroll patients in a new trial testing novel combination immunotherapies in pancreatic cancer. The study is a collaboration between CUMC/NYP and the Switzerland based pharmaceutical company F. Hoffmann-La Roche Ltd (Roche). It involves testing experimental combinations in MORPHEUS, Roche's novel cancer immunotherapy adaptive design platform. This approach is designed to investigate distinct immunotherapy combinations based on our understanding of pancreatic cancer biology and immunotherapy. Dr. Gulam Manji, the Principal Investigator at CUMC/NYP, is hopeful that this trial will bring the benefits of cancer immunotherapy to pancreatic cancer and allow for rapid testing of multiple combinations within a single clinical trial. Columbia is one of 23 expert institutions that make up the Roche-led imCORE Network for cancer immunotherapy research.

Related Links

HICCC Clinical Trials: http://cancer.columbia.edu/clinical-trials/phase-ibll-open-label-multicenter-randomized-umbrella-study-evaluating-efficacy-an-3

ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT03193190